FR2484254A1 - Compositions pharmaceutiq - Google Patents
Compositions pharmaceutiq Download PDFInfo
- Publication number
- FR2484254A1 FR2484254A1 FR8027873A FR8027873A FR2484254A1 FR 2484254 A1 FR2484254 A1 FR 2484254A1 FR 8027873 A FR8027873 A FR 8027873A FR 8027873 A FR8027873 A FR 8027873A FR 2484254 A1 FR2484254 A1 FR 2484254A1
- Authority
- FR
- France
- Prior art keywords
- potassium
- salt
- microcapsules
- weight
- micro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000003094 microcapsule Substances 0.000 claims abstract description 50
- 239000007903 gelatin capsule Substances 0.000 claims abstract description 19
- 239000011591 potassium Substances 0.000 claims abstract description 19
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 238000013270 controlled release Methods 0.000 claims abstract description 5
- 208000007645 potassium deficiency Diseases 0.000 claims abstract description 5
- 208000019025 Hypokalemia Diseases 0.000 claims abstract description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical group [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 54
- 239000004094 surface-active agent Substances 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 20
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 20
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 150000003109 potassium Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 37
- 239000001103 potassium chloride Substances 0.000 description 27
- 235000011164 potassium chloride Nutrition 0.000 description 26
- 229960003975 potassium Drugs 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000000576 coating method Methods 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000007922 dissolution test Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- -1 potassium cations Chemical class 0.000 description 7
- 210000001198 duodenum Anatomy 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 159000000001 potassium salts Chemical class 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005354 coacervation Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/159,335 US4259315A (en) | 1980-06-13 | 1980-06-13 | Controlled release potassium dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2484254A1 true FR2484254A1 (fr) | 1981-12-18 |
| FR2484254B1 FR2484254B1 (enExample) | 1983-06-10 |
Family
ID=22572135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8027873A Granted FR2484254A1 (fr) | 1980-06-13 | 1980-12-31 | Compositions pharmaceutiq |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4259315A (enExample) |
| JP (1) | JPS5714525A (enExample) |
| AU (1) | AU544965B2 (enExample) |
| BE (1) | BE886973A (enExample) |
| CA (1) | CA1135624A (enExample) |
| CH (1) | CH648206A5 (enExample) |
| DE (1) | DE3100808A1 (enExample) |
| FR (1) | FR2484254A1 (enExample) |
| GB (1) | GB2077587B (enExample) |
| IL (1) | IL61817A (enExample) |
| IT (1) | IT1212512B (enExample) |
| NL (1) | NL192430C (enExample) |
| PH (1) | PH15605A (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1148784B (it) * | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
| DK151608C (da) * | 1982-08-13 | 1988-06-20 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse |
| DK152744C (da) * | 1982-08-13 | 1988-10-31 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat |
| DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| DE3586600T2 (de) * | 1984-02-10 | 1993-02-18 | Benzon Pharma As | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. |
| EP0202222A1 (en) * | 1984-11-27 | 1986-11-26 | SAWRUK, Stephen, D. | Tissue re-calcification product |
| US4818539A (en) * | 1985-02-05 | 1989-04-04 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| US4851392A (en) * | 1985-02-05 | 1989-07-25 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| US4747881A (en) * | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| US4843098A (en) * | 1985-02-05 | 1989-06-27 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| US4790991A (en) * | 1985-02-05 | 1988-12-13 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
| ES8801121A1 (es) * | 1985-02-19 | 1988-01-01 | Key Pharma | Procedimiento de fabricacion de una unidad de dosificacion para la administracion oral de cloruro potasico. |
| US4874614A (en) * | 1985-03-25 | 1989-10-17 | Abbott Laboratories | Pharmaceutical tableting method |
| US4863741A (en) * | 1985-03-25 | 1989-09-05 | Abbott Laboratories | Tablet composition for drug combinations |
| US5095151A (en) * | 1985-05-21 | 1992-03-10 | American Home Products Corporation | Preparation of propranolol hydrochloride macrocrystals |
| US4764375A (en) * | 1985-09-11 | 1988-08-16 | Kv Pharmaceutical Company | Sachet drug delivery system |
| US4708834A (en) * | 1986-05-01 | 1987-11-24 | Pharmacaps, Inc. | Preparation of gelatin-encapsulated controlled release composition |
| US4795642A (en) * | 1986-05-01 | 1989-01-03 | Pharmacaps, Inc. | Gelatin-encapsulated controlled-release composition |
| FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
| US4822619A (en) * | 1987-02-18 | 1989-04-18 | Ionor, Inc. | Controlled release pharmaceutical preparation containing a gastrointestinal irritant drug |
| US5932252A (en) * | 1988-10-21 | 1999-08-03 | The Regents Of The University Of California | Method and composition for treatment of osteoporosis |
| US5498428A (en) * | 1988-10-21 | 1996-03-12 | The Regents Of The University Of California | Treatment of hypertension by oral administration of potassium bicarbonate |
| HU201869B (en) * | 1988-12-30 | 1991-01-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing microcapsules of quick dissolving active component |
| US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
| US5252337A (en) * | 1991-06-25 | 1993-10-12 | Eurand America, Inc. | Controlled release calcium channel blocker microcapsules |
| US5422122A (en) * | 1992-08-04 | 1995-06-06 | Eurand America, Incorporated | Controlled release potassium chloride tablet |
| US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| US5674529A (en) * | 1995-06-06 | 1997-10-07 | Church & Dwight Co., Inc. | Alkalinizing potassium salt controlled release preparations |
| US5895662A (en) * | 1997-12-31 | 1999-04-20 | Meyer; Martha C. | Meat product pet medicine capsule |
| NZ507951A (en) | 1998-04-09 | 2002-12-20 | Eurand Internat S | Wettable microcapsules having hydrophobic polymer coated cores |
| US6506401B1 (en) * | 1999-01-28 | 2003-01-14 | H. J. Heinz Company | Filled edible product, and system and method for production of a filled edible product |
| DE19913606A1 (de) * | 1999-03-25 | 2000-09-28 | Basf Ag | Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen |
| DE10011447A1 (de) * | 2000-03-10 | 2001-09-20 | Roehm Gmbh | Dispersion mit nichtionischem Emulgator |
| AU2001257359A1 (en) | 2000-04-27 | 2001-11-07 | Verion Inc. | Zero order release and temperature-controlled microcapsules and process for the preparation thereof |
| WO2001091730A1 (en) | 2000-05-31 | 2001-12-06 | Drugtech Corporation | Mineral supplement |
| JP4689114B2 (ja) * | 2000-11-02 | 2011-05-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ビタミンと加工大蒜を含有するカプセル剤 |
| US6780437B2 (en) * | 2001-10-23 | 2004-08-24 | Upsher-Smith Laboratories, Inc. | Coated potassium chloride granules and tablets |
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| US7538652B2 (en) * | 2006-08-29 | 2009-05-26 | International Business Machines Corporation | Electrical component tuned by conductive layer deletion |
| AU2008305243B2 (en) * | 2007-09-28 | 2013-09-12 | Lintec Corporation | Medicinal preparation for oral administration |
| US8974594B2 (en) * | 2011-03-29 | 2015-03-10 | Empire Technology Development Llc | Microcapsule corrosion control in reinforced concrete |
| DE102017201095A1 (de) * | 2017-01-24 | 2018-07-26 | Henkel Ag & Co. Kgaa | Tenside in Kapseln mit optimiertem Trübungspunkt |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2184902A1 (enExample) * | 1972-05-18 | 1973-12-28 | Sanol Arznei Schwarz Gmbh | |
| FR2279414A1 (fr) * | 1974-07-26 | 1976-02-20 | Smith Kline French Lab | Composition pharmaceutique comprenant des composes de magnesium et de potassium |
| US4140756A (en) * | 1976-06-10 | 1979-02-20 | Mead Johnson & Company | Film-coated matrix core tablet |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415758A (en) * | 1960-03-09 | 1968-12-10 | Ncr Co | Process of forming minute capsules en masse |
| JPS5112919A (en) * | 1974-07-19 | 1976-01-31 | Smith Kline French Lab | Johoseisoseibutsuno seiho |
-
1980
- 1980-06-13 US US06/159,335 patent/US4259315A/en not_active Expired - Lifetime
- 1980-12-29 IL IL61817A patent/IL61817A/xx not_active IP Right Cessation
- 1980-12-30 AU AU65898/80A patent/AU544965B2/en not_active Ceased
- 1980-12-31 CH CH9660/80A patent/CH648206A5/fr unknown
- 1980-12-31 FR FR8027873A patent/FR2484254A1/fr active Granted
-
1981
- 1981-01-06 BE BE0/203409A patent/BE886973A/fr not_active IP Right Cessation
- 1981-01-13 DE DE19813100808 patent/DE3100808A1/de active Granted
- 1981-01-22 IT IT8167071A patent/IT1212512B/it active
- 1981-01-26 GB GB8102250A patent/GB2077587B/en not_active Expired
- 1981-01-30 NL NL8100468A patent/NL192430C/nl not_active IP Right Cessation
- 1981-01-30 PH PH25154A patent/PH15605A/en unknown
- 1981-02-06 CA CA000370347A patent/CA1135624A/en not_active Expired
- 1981-02-23 JP JP2535281A patent/JPS5714525A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2184902A1 (enExample) * | 1972-05-18 | 1973-12-28 | Sanol Arznei Schwarz Gmbh | |
| FR2279414A1 (fr) * | 1974-07-26 | 1976-02-20 | Smith Kline French Lab | Composition pharmaceutique comprenant des composes de magnesium et de potassium |
| US4140756A (en) * | 1976-06-10 | 1979-02-20 | Mead Johnson & Company | Film-coated matrix core tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2077587B (en) | 1983-10-12 |
| NL192430B (nl) | 1997-04-01 |
| IT8167071A0 (it) | 1981-01-22 |
| NL192430C (nl) | 1997-08-04 |
| NL8100468A (nl) | 1982-01-04 |
| JPH0260649B2 (enExample) | 1990-12-17 |
| BE886973A (fr) | 1981-05-04 |
| IT1212512B (it) | 1989-11-22 |
| IL61817A0 (en) | 1981-01-30 |
| JPS5714525A (en) | 1982-01-25 |
| CH648206A5 (fr) | 1985-03-15 |
| FR2484254B1 (enExample) | 1983-06-10 |
| DE3100808C2 (enExample) | 1990-07-26 |
| AU544965B2 (en) | 1985-06-27 |
| AU6589880A (en) | 1981-12-24 |
| IL61817A (en) | 1983-11-30 |
| DE3100808A1 (de) | 1982-01-07 |
| US4259315A (en) | 1981-03-31 |
| CA1135624A (en) | 1982-11-16 |
| PH15605A (en) | 1983-02-28 |
| GB2077587A (en) | 1981-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2484254A1 (fr) | Compositions pharmaceutiq | |
| US5614222A (en) | Stable aqueous drug suspensions and methods for preparation thereof | |
| CA2493464C (fr) | Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os | |
| JP3233638B2 (ja) | 凍結乾燥された薬投与形状物の製造方法 | |
| EP1333816B1 (fr) | Medicament a base de microcapsules d'anti-hyperglycemiant a liberation prolongee et son procede de preparation | |
| BE1015217A5 (enExample) | ||
| JP2002522473A5 (enExample) | ||
| EP0830129B1 (fr) | Compositions solides contenant du polyethyleneoxyde et un principe actif non amorphe | |
| MC1101A1 (fr) | Composition a activite retardee | |
| CA2452239C (fr) | Formulation pharmaceutique au gout masque et son procede de preparation | |
| FR2752162A1 (fr) | Comprime de maleate de trimebutine pellicule | |
| TW200800305A (en) | Encapsulation of lipid-based formulations in enteric polymers | |
| FR2540727A1 (fr) | Nouvelle preparation retard contenant de la n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine, utile notamment dans le traitement de l'hypertension | |
| FR2695804A1 (fr) | Compositions nutritives ou médicamenteuses pour l'administration aux ruminants à base de chitosane. | |
| JPH10502358A (ja) | 作用物質の遊離遅延を伴うカルバマゼピン薬剤 | |
| JP2000514100A (ja) | 可溶化されたセルトラリン組成物 | |
| CN111867583B (zh) | 治疗溃疡性大肠炎的胶囊剂 | |
| EP0036345B1 (fr) | Nouveau procédé d'enrobage d'au moins un principe actif médicamenteux, les nouveaux médicaments ainsi obtenus, et les compositions les renfermant | |
| LU87233A1 (fr) | Composition pharmaceutique a base d'un anti-inflammatoire non steroidien,son procede de preparation et son utilisation | |
| FR2493146A1 (fr) | Melange de cromoglycate de sodium avec un excipient hydrosoluble et procede pour sa preparation pour traiter les affections du tractus gastro-intestinal | |
| HUT74741A (en) | Microgranules of 5-nitro imidazole derivatives and pharmaceutical compositions containing them | |
| FR2769853A1 (fr) | Nouveau procede d'obtention de microspheres et les produits ainsi realises | |
| CA2022447A1 (fr) | Forme galenique orale ameliorant la biodisponibilite | |
| FR2750859A1 (fr) | Composition pharmaceutique destinee a une administration par voie buccale avec absorption d'au moins un principe actif a travers les muqueuses de la bouche | |
| CA2598410A1 (fr) | Forme pharmaceutique orale de losartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |